Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?

Affiliations

¹ Medical Science, Kawasaki Medical School, Okayama, Japan. Electronic address: kms.cds.kanda@gmail.com.
² Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Free article

Comment

Eiichiro Kanda et al. Kidney Int. 2019 Jul.

Free article

. 2019 Jul;96(1):8-10.

doi: 10.1016/j.kint.2019.04.005.

¹ Medical Science, Kawasaki Medical School, Okayama, Japan. Electronic address: kms.cds.kanda@gmail.com.
² Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

No abstract available

Keywords: diabetic kidney disease; sodium-glucose cotransporters-2 inhibitor; systematic review; tubuloglomerular feedback.

Comment on

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. Circulation. 2019. PMID: 30786725